Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anticoagulation in the elderly.

M C Henderson1, R H White

  • 1Department of Internal Medicine, University of California-Davis, 4150 V Street, Sacramento, CA 95817, USA. mchenderson@ucdavis.edu

Current Opinion in Pulmonary Medicine
|October 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bermudagrass Dead Spot: A New Disease of Bermudagrass Caused by Ophiosphaerella agrostis.

Plant disease·2019
Same author

Predictors of post-thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study.

Journal of thrombosis and haemostasis : JTH·2012
Same author

Comparison of the Villalta post-thrombotic syndrome score in the ipsilateral vs. contralateral leg after a first unprovoked deep vein thrombosis.

Journal of thrombosis and haemostasis : JTH·2012
Same author

The biosynthesis of n-[(2)H (7)] fatty acids byArthrobacter globiformis from [U-(2)H (15)] octanoic acid.

Lipids·2011
Same author

Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study.

Journal of thrombosis and haemostasis : JTH·2011
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Oral anticoagulation therapy benefits elderly patients with atrial fibrillation and venous thromboembolism. Careful management is crucial due to increased bleeding and clotting risks in this population.

Area of Science:

  • Geriatrics
  • Pharmacology
  • Cardiology

Background:

  • Oral anticoagulation therapy is vital for preventing and treating thromboembolic disorders.
  • Elderly patients, particularly those with nonvalvular atrial fibrillation or venous thromboembolism, are common recipients of this therapy.
  • Anticoagulation in the elderly presents unique challenges due to heightened risks of both recurrent thromboembolism and major bleeding.

Purpose of the Study:

  • To review the pharmacology of warfarin in elderly patients.
  • To detail drug interactions and current dosing recommendations for this demographic.
  • To examine the evidence on the benefits and risks of oral anticoagulation in atrial fibrillation and venous thromboembolism.

Main Methods:

  • Literature review of warfarin pharmacology in the elderly.

Related Experiment Videos

  • Analysis of evidence regarding anticoagulation benefits and risks.
  • Synthesis of current dosing recommendations and drug interactions.

    • Main Results:

    • Warfarin's use in the elderly requires careful consideration of pharmacokinetics and pharmacodynamics.
    • Elderly patients face a dual risk of thromboembolic events and significant bleeding, including intracranial hemorrhage.
    • Specific drug interactions and appropriate dosing strategies are critical for safe and effective anticoagulation.

    Conclusions:

    • Oral anticoagulation therapy offers significant benefits for elderly patients with atrial fibrillation and venous thromboembolism.
    • Practitioners must meticulously weigh the risks of bleeding against the benefits of preventing thromboembolic events.
    • Informed treatment decisions require a thorough understanding of warfarin's use in the elderly, including drug interactions and dosing.